Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.65 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.65 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.46 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30569945 | 1.00 | PARP10 (0.65) | PARP10PARP3PARP15PARP14ALDH1A1 | |
| SCHEMBL15330339 | 0.91 | PARP10 (0.65) | PARP10PARP3PARP15PARP14ALDH1A1 | |
| SCHEMBL13772124 | 0.87 | PARP10 (0.51) | PARP10PARP3ALDH1A1OPRK1OPRM1 | |
| SCHEMBL3024115 | 0.85 | PARP10 (0.67) | PARP10PARP15PARP14ALDH1A1KMT2A | |
| SCHEMBL27245278 | 0.84 | PARP10 (0.62) | PARP10PARP15PARP14ALDH1A1KMT2A | |
| SCHEMBL3691706 | 0.83 | PARP10 (0.65) | PARP10PARP3PARP15PARP14ALDH1A1 | |
| SCHEMBL3701320 | 0.83 | PARP10 (0.65) | PARP10PARP3PARP15PARP14ALDH1A1 | |
| SCHEMBL3693691 | 0.82 | PARP10 (0.64) | PARP10PARP3PARP15PARP14ALDH1A1 | |
| SCHEMBL21628730 | 0.82 | PARP10 (0.59) | PARP10PARP15PARP14ALDH1A1KMT2A | |
| SCHEMBL26214383 | 0.82 | PARP10 (0.63) | PARP10PARP15PARP14ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326714-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | JANSSEN PHARMACEUTICALS INC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4489748-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | claimed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | claimed |
| WO-2023170547-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | claimed |
| US-20250326714-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | JANSSEN PHARMACEUTICALS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4489748-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-11-02 | — | — | US | disclosed |
| WO-2023170547-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170547-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230277500-A1 | COMPOSITIONS COMPRISING ATICAPRANT | Janssen Pharmaceuticals, Inc. | 2023-09-07 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1562595-B1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277500-A1 | COMPOSITIONS COMPRISING ATICAPRANT | ADORA1, ADORA2B, ADORA2A | PARP10 1229/4885PARP3 416/4885PARP15 897/4885 |
| US-20230348377-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | ATIC, ADORA1, ADORA2A | PARP10 4198/4885PARP3 3010/4885PARP15 4244/4885 |
| US-20250326714-A1 | PURE FORMS OF CRYSTALLINE ATICAPRANT | ATIC, ADORA1, ADORA2A | PARP10 4198/4885PARP3 3010/4885PARP15 4244/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | PARP10 2434/4885PARP3 4263/4885PARP15 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.